No accelerated approval for olaparib


The FDA's Oncologic Drugs Advisory Committee votes 11-2 in favor of requiring AstraZeneca (AZN +0.9%) to submit additional clinical data demonstrating the efficacy of olaparib as a treatment for ovarian cancer before it will consider recommending approval. The panel's opinion was that the data the company submitted in its application was not robust enough to prove it could be reproduced. Committee members also voiced concern about a potential risk of secondary cancers in patients receiving the drug.

The vote means that regulatory clearance will not happen until at least 2016.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs